» Articles » PMID: 38182279

Heightened Long-term Cardiovascular Risks After Exacerbation of Chronic Obstructive Pulmonary Disease

Overview
Journal Heart
Date 2024 Jan 5
PMID 38182279
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To examine the risk of adverse cardiovascular (CV) events following an exacerbation of chronic obstructive pulmonary disease (COPD).

Methods: This retrospective cohort study identified patients with COPD using administrative data from Alberta, Canada from 2014 to 2019. Exposure periods were 12 months following moderate or severe exacerbations; the reference period was time preceding a first exacerbation. The primary outcome was the composite of all-cause death or a first hospitalisation for acute coronary syndrome, heart failure (HF), arrhythmia or cerebral ischaemia. Time-dependent Cox regression models estimated covariate-adjusted risks associated with six exposure subperiods following exacerbation.

Results: Among 1 42 787 patients (mean age 68.1 years and 51.7% men) 61 981 (43.4%) experienced at least one exacerbation and 34 068 (23.9%) died during median follow-up of 64 months. The primary outcome occurred in 43 564 (30.5%) patients with an incidence rate prior to exacerbation of 5.43 (95% CI 5.36 to 5.50) per 100 person-years. This increased to 95.61 per 100 person-years in the 1-7 days postexacerbation (adjusted HR 15.86, 95% CI 15.17 to 16.58) and remained increased for up to 1 year. The risk of both the composite and individual CV events was increased following either a moderate or a severe exacerbation, though greater and more prolonged following severe exacerbation. The highest magnitude of increased risk was observed for HF decompensation (1-7 days, HR 72.34, 95% CI 64.43 to 81.22).

Conclusion: Moderate and severe COPD exacerbations are independent risk factors for adverse CV events, especially HF decompensation. The impact of optimising COPD management on CV outcomes should be evaluated.

Citing Articles

Endothelial dysfunction in chronic obstructive pulmonary disease: an update on mechanisms, assessment tools and treatment strategies.

Marcuccio G, Candia C, Maniscalco M, Ambrosino P Front Med (Lausanne). 2025; 12:1550716.

PMID: 40046916 PMC: 11880998. DOI: 10.3389/fmed.2025.1550716.


Diagnosis and management of comorbid disease in COPD.

Cronin E, Cushen B Breathe (Sheff). 2025; 21(1):240099.

PMID: 40007528 PMC: 11851148. DOI: 10.1183/20734735.0099-2024.


Temporal Dynamics of Cardiovascular Risk in Patients with Chronic Obstructive Pulmonary Disease During Stable Disease and Exacerbations: Review of the Mechanisms and Implications.

Simons S, Heptinstall A, Marjenberg Z, Marshall J, Mullerova H, Rogliani P Int J Chron Obstruct Pulmon Dis. 2024; 19:2259-2271.

PMID: 39411574 PMC: 11474009. DOI: 10.2147/COPD.S466280.


A Multi-Specialty Delphi Consensus on Assessing and Managing Cardiopulmonary Risk in Patients with COPD.

Bhutani M, Bourbeau J, Goodman S, Hawkins N, Kaplan A, Lin P Int J Chron Obstruct Pulmon Dis. 2024; 19:2051-2062.

PMID: 39318837 PMC: 11420896. DOI: 10.2147/COPD.S471952.


A Research Agenda to Improve Outcomes in Patients with Chronic Obstructive Pulmonary Disease and Cardiovascular Disease: An Official American Thoracic Society Research Statement.

Myers L, Quint J, Hawkins N, Putcha N, Hamilton A, Lindenauer P Am J Respir Crit Care Med. 2024; 210(6):715-729.

PMID: 39133888 PMC: 11418885. DOI: 10.1164/rccm.202407-1320ST.


References
1.
van Eeden S, Leipsic J, Paul Man S, Sin D . The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med. 2012; 186(1):11-6. DOI: 10.1164/rccm.201203-0455PP. View

2.
Agusti A, Celli B, Criner G, Halpin D, Anzueto A, Barnes P . Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. Eur Respir J. 2023; 61(4). PMC: 10066569. DOI: 10.1183/13993003.00239-2023. View

3.
Halpin D, Decramer M, Celli B, Kesten S, Leimer I, Tashkin D . Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial. Lung. 2011; 189(4):261-8. PMC: 3140935. DOI: 10.1007/s00408-011-9301-8. View

4.
Hawkins N, Peterson S, Ezzat A, Vijh R, Virani S, Gibb A . Control of Cardiovascular Risk Factors in Patients with Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2022; 19(7):1102-1111. DOI: 10.1513/AnnalsATS.202104-463OC. View

5.
Rothnie K, Connell O, Mullerova H, Smeeth L, Pearce N, Douglas I . Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2018; 15(8):935-946. PMC: 6322039. DOI: 10.1513/AnnalsATS.201710-815OC. View